<DOC>
	<DOCNO>NCT01929876</DOCNO>
	<brief_summary>This open-label , 2-period , fixed sequence , drug interaction study investigate effect co-administration itraconazole pharmacokinetics cobimetinib healthy participant . Participants receive multiple repeating dos cobimetinib itraconazole .</brief_summary>
	<brief_title>A Study Evaluate Effect Itraconazole Pharmacokinetics Cobimetinib Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Healthy adult participant Within body mass index ( BMI ) range 18.5 32 kilogram per meter square ( kg/m^2 ) , inclusive Creatine phosphokinase level 2.5 time upper limit normal ( ULN ) elevate , clinically significant Liver function test aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase 2 time ULN ; bilirubin 1.5 time ULN ; liver function test elevation clinically significant In good health , determine clinically significant finding medical history , 12lead electrocardiogram ( ECG ) , vital sign Clinical laboratory evaluation within reference range test laboratory , unless deem clinically significant Investigator Negative test select drug abuse screen checkin Negative hepatitis panel ( include hepatitis B surface antigen [ HBsAg ] antihepatitis C virus [ HCV ] ) negative human immunodeficiency virus ( HIV ) antibody screen Females nonpregnant nonlactating Males female ( childbearing potential ) use two form adequate contraception Significant history clinical manifestation metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug ; except appendectomy , hernia repair , and/or cholecystectomy allow History diabetes mellitus and/or elevate fast glucose baseline History presence abnormal ECG , Investigator 's opinion , clinically significant History alcoholism drug addiction within 1 year prior study start Use tobacco nicotinecontaining product ( within 6 month prior study start entire study Participation investigational study biologic agent trial receipt investigational study drug occur within 5 halflives 30 day , whichever longer , exposure biological therapy investigational biological agent within 90 day prior study entry entire study study start study completion , inclusive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>